Business Description
Novartis India Ltd
NAICS : 325412
ISIN : INE234A01025
Compare
Compare
Traded in other countries / regions
500672.India IPO Date
1991-01-02Description
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment namely Pharmaceutical Business, Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 99.12 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.07 | |||||
| Interest Coverage | 109.93 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 10.27 | |||||
| Beneish M-Score | -2.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3 | |||||
| 3-Year EBITDA Growth Rate | 28.5 | |||||
| 3-Year EPS without NRI Growth Rate | 66.7 | |||||
| 3-Year Book Growth Rate | 1.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.26 | |||||
| 9-Day RSI | 27.64 | |||||
| 14-Day RSI | 32.25 | |||||
| 6-1 Month Momentum % | -6.43 | |||||
| 12-1 Month Momentum % | 44.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.96 | |||||
| Quick Ratio | 4.72 | |||||
| Cash Ratio | 4.26 | |||||
| Days Inventory | 94.76 | |||||
| Days Sales Outstanding | 59.63 | |||||
| Days Payable | 114.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.63 | |||||
| Dividend Payout Ratio | 1.04 | |||||
| Forward Dividend Yield % | 2.63 | |||||
| 5-Year Yield-on-Cost % | 2.64 | |||||
| Shareholder Yield % | 2.82 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.81 | |||||
| Operating Margin % | 20.09 | |||||
| Net Margin % | 24.49 | |||||
| FCF Margin % | 45.04 | |||||
| ROE % | 8.5 | |||||
| ROA % | 6.88 | |||||
| ROIC % | 11.05 | |||||
| ROC (Joel Greenblatt) % | 1333.09 | |||||
| ROCE % | 12.09 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.07 | |||||
| PE Ratio without NRI | 39.65 | |||||
| Shiller PE Ratio | 32.68 | |||||
| Price-to-Owner-Earnings | 24.3 | |||||
| PEG Ratio | 4.78 | |||||
| PS Ratio | 9.32 | |||||
| PB Ratio | 3.22 | |||||
| Price-to-Tangible-Book | 3.22 | |||||
| Price-to-Free-Cash-Flow | 20.7 | |||||
| Price-to-Operating-Cash-Flow | 20.7 | |||||
| EV-to-EBIT | 19.37 | |||||
| EV-to-EBITDA | 19.16 | |||||
| EV-to-Revenue | 6.97 | |||||
| EV-to-FCF | 15.43 | |||||
| Price-to-Projected-FCF | 3.5 | |||||
| Price-to-Median-PS-Value | 2.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.92 | |||||
| Price-to-Graham-Number | 2.01 | |||||
| Price-to-Net-Current-Asset-Value | 4.4 | |||||
| Price-to-Net-Cash | 5.38 | |||||
| Earnings Yield (Greenblatt) % | 5.16 | |||||
| FCF Yield % | 4.83 | |||||
| Forward Rate of Return (Yacktman) % | 7.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis India Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,517.8 | ||
| EPS (TTM) (₹) | 24.97 | ||
| Beta | 1.07 | ||
| Volatility % | 31.13 | ||
| 14-Day RSI | 32.25 | ||
| 14-Day ATR (₹) | 32.054169 | ||
| 20-Day SMA (₹) | 1022.6075 | ||
| 12-1 Month Momentum % | 44.16 | ||
| 52-Week Range (₹) | 708 - 1248 | ||
| Shares Outstanding (Mil) | 24.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis India Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis India Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis India Ltd Frequently Asked Questions
What is Novartis India Ltd(BOM:500672)'s stock price today?
The current price of BOM:500672 is ₹950.60. The 52 week high of BOM:500672 is ₹1248.00 and 52 week low is ₹708.00.
When is next earnings date of Novartis India Ltd(BOM:500672)?
The next earnings date of Novartis India Ltd(BOM:500672) is .
Does Novartis India Ltd(BOM:500672) pay dividends? If so, how much?
The Dividend Yield %  of Novartis India Ltd(BOM:500672) is 2.63% (As of Today), Highest Dividend Payout Ratio of Novartis India Ltd(BOM:500672) was 2.37. The lowest was 0.23. And the median was 0.57. The  Forward Dividend Yield % of Novartis India Ltd(BOM:500672) is 2.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers